Methylene tetrahydrofolate reductase (MTHFR) gene polymorphisms in chronic myeloid leukemia: An Egyptian study

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Khorshied, Mervat Mamdooh ^a,b   Shaheen, Iman Abdel Mohsen ^a   Abu Khalil, Reham E ^a   Sheir, Rania Elsayed ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b Beni Sweif University ^*  (Egypt)

^c BENI SUEF UNIVERSITY   (Egypt)

Author keywords

A1298C; CML; Egypt; MTHFR C677T

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2) GENE; ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EGYPT; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ALLELE; CASE CONTROL STUDY; DNA METHYLATION; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; HOMOZYGOTE;

METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ADULT; ALLELES; CASE-CONTROL STUDIES; DNA METHYLATION; EGYPT; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HOMOZYGOTE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC;

MLCS; MLOWN;

EID: 84889796055     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0794-2     Document Type: Article

References (28)

1. Albano F, Zagaria A, Coccaro N, Impera L, Minervini CF, Minervini A, Rossi AR, Tota G, Casieri P. Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation. Mol Cancer. 2013;12:36.
2. Lordelo GS, Miranda-Vilela AL, Akimoto AK, Alves PC, Hiragi CO, Nonino A, Daldegan MB, Klautau-Guimarães MN, Grisolia CK. Association between methylene tetrahydrofolate reductase and glutathione S-transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population. Genet Mol Res. 2012;11(2):1013-26.
3. Nowicki MO, Falinski R, Koptyra M, Slupianek A, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 2004;104:3746-53. (Pubitemid 39564453)
4. Kim DH, Xu W, Ma C, Liu X, et al. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood. 2009;113:2517-25.
5. Zagaria A, Anelli L, Albano F, Storlazzi CT, Liso A, Roberti MG, Buquicchio C, Liso V, Rocchi M, Specchia G. A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome. Cancer Genet Cytogenet. 2004;150:81-5. (Pubitemid 38369254)
6. Gouda HM, Abdel Mohsen MM. Frequency of expression of RHAMM/CD168 in Egyptian patients with CML. J Egypt Natl Canc Inst. 2009;21(2):93-9.
7. Robien K, Ulrich CM, Bigler J, Yasui Y, Gooley T, Bruemmer B. Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin Cancer Res. 2004;10(22):7592-8. (Pubitemid 39557521)
8. Vahid P, Farnaz R, Zaker F, Farzaneh A, Parisa R. Methylenetetrahydrofolate Reductase gene polymorphisms and risk of myeloid leukemia. Lab Med. 2010;41:490-4.
9. Bowen DT, Frew ME, Rollinson S, Roddam PL, et al. CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. Blood. 2003;101:2770-4. (Pubitemid 36857642)
10. Miranda-Vilela AL. Role of polymorphisms in factor V (FV Leiden), prothrombin, plasminogen activator inhibitor type-1 (PAI-1), methylenetetrahydrofolate reductase (MTHFR) and Cystathionine ß-synthase (CBS) genes as risk factors for thrombophilias. Mini Rev Med Chem. 2012;12:997-1006.
11. Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, Greaves MF. United Kingdom childhood cancer study investigators. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A. 2001;98(7):4004-9. (Pubitemid 32249888)
12. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-3.
13. Murphy TM, Perry AS, Lawler M. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr Relat Cancer. 2008;15:11-25. (Pubitemid 351449724)
14. Sinthuwiwat T, Poowasanpetch P, Wongngamrungroj A, Soonklang K, Promso S, et al. Association of MTHFR polymorphisms and chromosomal abnormalities in leukemia. Dis Markers. 2012;32:115-21.
15. Zhu J, Wu L, Kohlmeier M, Ye F, Cai W. Association between MTHFR C677T, MTHFR A1298C and MS A2756G polymorphisms and risk of cervical intraepithelial neoplasia II/III and cervical cancer: a meta-analysis. Mol Med Rep. 2013;8(3):919-27.
16. Robien K, Bigler J, Yasui Y, Potter JD, Martin P, Storb R, Ulrich CM. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2006;12(9):973-80.
17. van der Put NM, Gabreëls F, Stevens EM, Smeitink JA, Trijbels FJ, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998;62:1044-51. (Pubitemid 28199004)
18. Suarez-Kurtz G. Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network-REFARGEN. Pharmacogenomics J. 2004;4:347-8. (Pubitemid 39600048)
19. Barreiro LB, Laval G, Quach H, Patin E, et al. Natural selection has driven population differentiation in modern humans. Nat Genet. 2008;40:340-5. (Pubitemid 351311765)
20. Jakovljevic K, Malisic E, Cavic M, Radulovic S, Jankovic R. Association between methylenetetrahydrofolate reductase polymorphism C677T and risk of chronic myeloid leukemia in Serbian population. Leuk Lymphoma. 2012;53(7):1327-30. doi: 0.3109/10428194.2011.645210.
21. Weisberg IS, Jacques PF, Selhub J, et al. The 1298A->C poly-morphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001;156:409-15. (Pubitemid 32522922)
22. Li D, Tian T, Guo C, Ren J, Yan L, Liu H, Xu Z. No association of the MTHFR gene A1298C polymorphism with the risk of prostate cancer: a meta-analysis. Exp Ther Med. 2012;3(3):493-8.
23. Ismail SI, Ababneh NA, Awidi A. Methylenetetrahydrofolate Reductase (MTHFR) genotype association with the risk of chronic myelogenous leukemia. Jorden Med J. 2009;43(1):8-14.
24. Hussain SR, Naqvi H, Raza ST, Ahmed F, Babu SG, Kumar A, Zaidi ZH, Mahdi F. Methylenetetrahydrofolate reductase C677T genetic polymorphisms and risk of leukaemia among the North Indian population. Cancer Epidemiol. 2012;36(4):e227-31. doi: 10.1016/j.canep.2012.02.008.
25. Moon HW, Kim TY, Oh BR, Min HC, Cho HI, Bang SM, Lee JH, Yoon SS, Lee DS. MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea. Leuk Res. 2007;31(9):1213-7.
26. Hur M, Park JY, Cho HC, Lee KM, Shin HY, Cho HI. Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population. Clin Lab Haematol. 2006;28(3):154-9.
27. Grillo LB, Acácio GL, Barini R, Pinto W Jr, Bertuzzo CS. Mutations in the methylene-tetrahydrofolate reductase gene and down syndrome. Cad Saude Publica. 2002;6:1795-7.
28. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76-94. (Pubitemid 34264171)